⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Actinogen Medical and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Actinogen Medical
↗Sydney, Australia
Actinogen Medical is an Australian clinical-stage biotechnology company focused on developing novel therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol. Its lead candidate, Xanamem (emestedastat), is a first-in-class, brain-penetrant 11β-HSD1 inhibitor designed to treat cognitive impairment in conditions such as Alzheimer's disease and major depressive disorder.
The company is listed on the Australian Securities Exchange (ASX: ACW) and is headquartered in Sydney, Australia. Actinogen utilizes a clinical-stage development model, conducting trials in Australia and the United States, and benefits from Australian R&D tax incentives to support its research and development programs.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Founded:1999
Ownership:public
Status:operating
FUNDING
Stage:Public
STOCK
Exchange:ASX
Ticker:ACW
Market Cap:$0.17B
PIPELINE
Stage:Phase 2/3
Lead Drug Stage:Phase 2/3
Modalities:Small molecule
Active Trials:1
Trial Phases:Phase 2: 1 | Phase 3: 1
FDA Approvals:0
EMA Approvals:0
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
Steven Gourlay - CEO & Managing Director
Dana C. Hilt - Chief Medical Officer
Will Souter - Chief Financial Officer
Board Members:Geoffrey Edward Duncan Brooke, George Morstyn, Malcolm John McComas, Nicki Vasquez
LINKS
Website:actinogen.com.au
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Actinogen Medical. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.